For over a decade, healthcare facilities in the United States have been grappling with the specter of carbapenem-resistant Enterobacterales (CRE). This group of bacteria has returned with a vengeance, thanks to the rise of the New Delhi metallo-β-lactamase-producing CRE (NDM-CRE), a formidable foe resistant to multiple therapeutic options.
The Centers for Disease Control and Prevention (CDC)…